IDEAYA Biosciences 株価情報 (NASDAQ: IDYA)

最新ニュース IDEAYA Biosciences (NASDAQ:IDYA) 株価情報

IDEAYA BIOSCIENCES INC

IDEAYA Biosciences

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

IDEAYA Biosciences Inc

Morgan Stanley analyst Christopher Snyder maintains Acuity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) with a Overweight and raises the price target from $335 to $365.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Acuity, Raises Price Target to $365

Most 11-year-olds are worried about math homework. Mallory Marshall was asking <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/06/46067598/bill-gates-kids-were-stunned-to-find-warren-buffett-chowing-down-on-oreos-for-breakfast-after-a-sleepover-naturally-they-demanded-some-too">Warren Buffett</a> how to build wealth. And Buffett—never one to miss an opportunity for both wisdom and a one-liner—delivered.
At the 2001 Berkshire Hathaway meeting, Mallory stepped up to the mic and opened with a crowd-pleaser:
"First, my dad would like to know if you have any grandsons my age."
Buffett didn't hesitate:
"How many shares of stock do you have? And I'll tell you."
Don't Miss:
<ul class="wp-block-list">
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
He added, "I've got a grandson fairly close to your age and he probably would go for a younger woman anyway… I will mention you to him."
But once the laughter faded, Mallory hit him with the real question:
"What investment advice do you have for young people of my generation?"
Buffett's answer wasn't about stock picks or complex finance. It was about having a head start—and knowing what to do with it.
"I was fortunate in that respect because my dad paid for my education. If he hadn't, I probably wouldn't have become educated if I had to pay for it myself… So I was able to save $10,000 by the time I was 21. And, you know, that was a huge, huge head start."
Trending: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a>
"It's much easier to save in those teenage years if you're lucky enough to be in a family where… your parents are taking care of your financial obligations. Every dollar then is, you know, worth making $10 or $20 later on."
"You have to have a little money to work with," he said. But what you do with it—that's the kicker.
His <a href="https://www.benzinga.com/personal-finance/25/02/43718032/warren-buffett-was-asked-how-a-regular-person-gets-rich-he-detailed-exactly-how-hed-make-30-billion-starting-over-with-only-10000">blueprint was simple</a>:
"Read financial publications. I'd be curious about how the businesses around the town of Kearney operated. Learn about who's got good businesses… and the businesses that went out of business and why."
"Everything is cumulative," Buffett added. "The stuff I learned when I was 20 is useful today… You're building a database in your mind that is going to pay off over time."
He even squeezed in a bit of practical advice for anyone with a wallet:
"There's nothing like getting a few dollars ahead. Stay away from credit cards."
Charlie Munger, ever the realist, chimed in with:
"Well, I'm glad to see somebody that has, so early, shown an interest in getting ahead. There's nothing wrong with getting ahead."
See Also: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
Then the two couldn't help circling back to the matchmaking suggestion.
"Actually, she may have the best idea about getting ahead by learning the name of my grandson," Buffett joked.
Munger added, "Before your feelings totally take over, you should <a href="https://www.benzinga.com/personal-finance/24/07/39963533/warren-buffett-says-the-most-important-decision-of-your-life-is-who-you-marry-his-biggest-mistak">look carefully at both parents</a> and all four grandparents."
And Buffett signed off with, "Write Charlie and let us know how it works out."
Now, of course, you can't control who your grandparents are. Buffett himself has famously called this the "ovarian lottery"—the idea that so much of your life's outcome is determined by the luck of birth. And he's not wrong. You don't get to pick your starting line.
But you do get to <a href="https://www.benzinga.com/general/education/25/05/45607543/warren-buffett-you-can-make-a-fortune-but-your-life-is-a-disaster-if-you-overlook-this-one-thing">pick how you run the race</a>. You can build that mental database. You can read, ask questions, stash cash, and skip the credit cards.
And maybe — just maybe — ask about the grandkids.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.

Personal Finance

Warren Buffett Told 11-Year-Old She Could Get Ahead In Life By Marrying His Grandson — Then Dropped Some Real Get-Rich Advice

Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.9%. Currently, Progressive has a market capitalization of $154.56 billion. 
Buying $1000 In PGR: If an investor had bought $1000 of PGR stock 5 years ago, it would be worth $3,363.01 today based on a price of $263.66 for PGR at the time of writing.
<h3>Progressive's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751039111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Progressive Stock In The Last 5 Years

WIIM

AMIX

Autonomix Medical shares are trading higher after the company announced it was granted a US Patent for its catheter-based platform technology.

EXOZ

ExoZymes shares are trading higher after the company announced it has been selected as a core industry partner in a $9 million NSF-funded initiative to advance modular cell-free biomanufacturing.

Morgan Stanley analyst Alex Straton maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Equal-Weight and raises the price target from $61 to $64.

Morgan Stanley Maintains Equal-Weight on Nike, Raises Price Target to $64

RDZN

Roadzen shares are trading higher after the company reported better-than-expected Q4 EPS results.

Time Magazine&#8217;s annual 100 Most Influential Companies list for 2025 includes many companies investors are familiar with, with numerous names originating from the growing <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence sector.</a>
The <a href="https://time.com/7297630/time-reveals-the-2025-time100-most-influential-companies-in-the-world/">list</a> seeks to honor the top businesses that are helping "chart an essential path forward."
"No single data point or financial metric makes a TIME100 Company. Instead, we looked at a mosaic of qualities, studying impact, innovation, ambition, and success, each in the forms that take shape today. And as we say for all TIME100 projects: influence comes in many forms, for better and for worse," Time editors said of the list.
 The Public Companies: Similar to the list of the <a href="https://www.benzinga.com/general/entertainment/25/04/44854679/time-100-most-influential-people-includes-elon-musk-mark-zuckerberg-alex-karp-and-more-public-company-ceos">Most Influential People</a> that Time published earlier this year, the list of influential companies includes top tech, AI, crypto, and healthcare names that are experiencing impressive growth and bringing life-changing technology to consumers or other companies.
Here is the list of publicly traded companies or those that are part of a publicly traded company. It is broken down by the key groups used by Time: Innovators, Disruptors, Leaders, Titans and Pioneers.
Innovators
<ul class="wp-block-list">
<li>On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>): footwear</li>
<li>Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>): Chinese e-commerce</li>
<li>Nintendo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>): video games</li>
<li>BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>): electric vehicles</li>
<li>Gap, unit of Gap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>): apparel</li>
<li>Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>): sports and outdoor retailer</li>
<li>EssilorLuxottica (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESLOY#OTC">ESLOY</a>): sunglasses, optical wear</li>
</ul>
Disruptors
<ul class="wp-block-list">
<li>Waymo, unit of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</li>
<li>Life Time Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>): fitness centers</li>
<li>Elf Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>): beauty products</li>
<li>Poppi, unit of PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): beverages</li>
<li>UFC, unit of TKO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>): fighting sports league</li>
<li>Pop Mart (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PMRTY#OTC">PMRTY</a>): pop culture retailer</li>
<li>Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): cryptocurrency trading platform</li>
<li>SharkNinja Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>): home appliances</li>
</ul>
Leaders
<ul class="wp-block-list">
<li>Engie (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ENGIY#OTC">ENGIY</a>): energy company</li>
<li>Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>): industrial and logistics real estate</li>
<li>Cloudflare Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NET#NASDAQ">NET</a>): a software company</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): biotechnology, healthcare</li>
<li>Duolingo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>): mobile learning</li>
<li>BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>): financials</li>
<li>Hyundai Motor (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMTF#OTC">HYMTF</a>): automotives</li>
<li>LinkedIn, unit of Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): social networking</li>
<li>Coursera Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>): online learning</li>
</ul>
Titans
<ul class="wp-block-list">
<li>Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>): conglomerate</li>
<li>Comcast, NBC Universal, units of Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>): media and entertainment</li>
<li>L'Oreal (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LRLCY#OTC">LRLCY</a>): beauty company</li>
<li>DoorDash Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>): food delivery</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>): social networking</li>
<li>Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>): a software company</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): e-commerce</li>
<li>Arm Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>): semiconductors</li>
<li>Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): consumer products</li>
<li>Fiserv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>): financial technology</li>
<li>MercadoLibre Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>): Latin American e-commerce</li>
<li>Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>): retailer</li>
<li>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>): streaming</li>
<li>Taiwan Semiconductor Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>): semiconductors</li>
<li>Universal Music Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UNVGY#OTC">UNVGY</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/UMGNF#OTC">UMGNF</a>): music publishing</li>
</ul>
Pioneers
<ul class="wp-block-list">
<li>ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>): semiconductors</li>
<li>Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>): oil and gas</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): medical devices</li>
<li>Softbank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>): telecom and e-commerce conglomerate</li>
<li>CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): gene editing</li>
</ul>
Read Also: <a href="https://www.benzinga.com/general/social-media/24/09/40760039/elon-musk-less-influential-to-artificial-intelligence-than-scarlett-johansson-time-magazine-">Elon Musk Less Influential To Artificial Intelligence Than Scarlett Johansson, Time Magazine Says: Billionaire Brushes Off Exclusion – &#8216;Magazines Do Not Establish Relevance, History Does&#8217;</a>
Why It's Important: Nearly half of this year's list includes companies that are publicly traded or part of publicly traded companies. This means investors can get exposure to what Time considers some of the most influential companies in the world.
Some of the companies are newer to the public market, which could mean that the 50+ companies that are not yet public could be among IPOs to watch for in the second half of 2025 and beyond.
Some of the most recognizable private companies on this year's list include OpenAI, Polymarket, Anthropic, Anduril, Beast Industries and SpaceX.
When seeking companies that can drive revenue growth and gain customer and consumer adoption, the most influential lists can be a valuable starting point for investors.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/25/03/44367926/mark-cuban-kevin-oleary-rejected-poppi-on-shark-tank-pepsi-just-paid-1-9-billion-to-acquire-company">Mark Cuban, Kevin O&#8217;Leary Rejected Poppi On Shark Tank, Pepsi Just Paid $1.9 Billion To Acquire Company</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Tech

Media

AMZN

ASML

BABA

BYDDF

BYDDY

CMCSA

COIN

COUR

CRSP

DASH

DUOL

ENGIY

EQNR

ESLOY

GILD

GOOG

GOOGL

HYMTF

LRLCY

MELI

MSFT

NFLX

NTDOY

ONON

PLTR

PMRTY

SFTBF

SFTBY

UMGNF

UNVGY

44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy

<a href="https://www.bloomberg.com/news/articles/2025-06-27/opec-is-set-to-weigh-another-super-sized-oil-output-increase" title="https://www.bloomberg.com/news/articles/2025-06-27/opec-is-set-to-weigh-another-super-sized-oil-output-increase">https://www.bloomberg.com/news/articles/2025-06-27/opec-is-set-to-weigh-another-super-sized-oil-output-increase</a>

Macro Economic Events

Global

Economics

'OPEC+ Is Set To Weigh Another Super-Sized Oil Output Increase' - Bloomberg News

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074819/PPIO.png" alt="" class="wp-image-14979" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074819/PPIO.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074819/PPIO-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074819/PPIO-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The provider of cloud services wants to upgrade its systems as AI moves into the mainstream, demanding greater processing capacity and speed 
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>The loss-making company has filed for an IPO to raise fresh funds to meet the anticipated growth in AI-related demand</li>
<li>It specializes in localized "edge" processing for faster response times, with revenues jumping 56% last year &nbsp;&nbsp;</li>
<li></li>
</ul>
As AI technology takes off, more computing power will be needed to apply generative learning to practical tasks and new contexts. This process, known in the industry as inference, could drive exponential demand for cloud services.
Gearing up for a fight over processing bandwidth, a Chinese provider of cloud services has applied to list on the Hong Kong Stock Exchange, with global ambitions to help empower the next phase of the AI revolution.
In its&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107464/documents/sehk25062001135.pdf">prospectus</a>, PPLabs Technology Ltd.,&nbsp;the parent of cloud services provider PPIO, cited plans to upgrade its AI-related services and develop its overseas presence in distributed cloud computing. The company describes itself as as pioneer of cloud services in China for AI tasks, ranking second among independent providers for average daily use.
The daily consumption rate in May reached 141.9 billion tokens, the system used by the computing industry to measure and price its operations.
<h4 class="wp-block-heading">Second chances</h4>
Company founder Yao Xin is no stranger to the tech industry. As a graduate student at Huazhong University of Science and Technology, Yao founded China's earliest online video platform in 2005. PPLive Media, later rebranded as PPTV, made its debut a year before YouTube, raising $700 million in capital before being sold to retailer Suning in 2014. At that point Yao paused his entrepreneurial activities.
Returning with the launch of PPIO in 2018, he focused the new business on an aspect of cloud computing that was not yet dominated by tech giants. The company set out to specialize in distributed edge computing, which aims to process data close to where it is generated.
The moves reflect shifting dynamics in cloud computing with the transformative advent of artificial intelligence. The costs of rolling out extrapolative AI systems and the challenge of allocating computing resources to them are causing bottlenecks. A capacity battle is brewing over the responsiveness to AI requests, in which edge computing can offer a proximity advantage.
Take the example of a Beijing user interacting with an AI assistant. If the task is handled at a U.S. data center, response delays are hard to avoid, even with optimized network transmission. However, a request routed via a node in Beijing or Hebei could be processed more like a real-time experience, which is particularly critical for voice, video, or gaming applications.
According to China Insights Consultancy, the edge cloud computing market in China is set to reach 37 billion yuan ($5.16 billion) in revenue by 2029, with a compound annual growth rate (CAGR) of 22.9% from 2024 to 2029. The global market was projected to achieve a CAGR of 68.5% over the same period, reaching 427.7 billion yuan in 2029.
Companies offering edge cloud services could become vital links in the AI industry chain, connecting infrastructure providers such as telecom operators with suppliers of processing hardware while packaging and distributing computing power along the way, and supporting AI developers.
PPIO has built a distributed computing network covering more than 1,200 cities and 4,000 nodes worldwide through its own infrastructure and partnerships.&nbsp; Using a scheduling platform developed in house, the network enables AI tasks to be automatically routed to the nearest available resource.
<h4 class="wp-block-heading">An Airbnb model?</h4>
The business monetizes the market in three ways. Firstly, computing power resources are provided to developers on demand, with billing based on duration or the tokens consumed. This income stream accounts for around 70% of revenue. In edge node services, idle hardware from enterprises or developers is co-opted into the node network, generating revenue through shared computing power. The company also offers customized AI applications, including services for small-model reasoning and systems to distribute content to nearby networks.
With its business still in the expansionary phase, PPIO has yet to break even. Still, it compares favorably to some cloud service startups, with relatively contained losses and a gross profit margin above 10%.
Figures in the IPO filing show that its turnover and losses have both been rising. The company logged revenues of 286 million yuan in 2022, increasing to 358 million yuan a year later and jumping nearly 56% in 2024 to 558 million yuan, a CAGR over the period of nearly 40%. Gross profit margins were 16.1%, 17.7% and 12.3%, while losses amounted to 85 million yuan, 189.4 million yuan and 293.5 million yuan, totaling around 568 million yuan for the three-year period.
The way PPIO aggregates idle processing resources and uses multi-node scheduling for AI tasks is similar to Airbnb approach of utilizing idle rooms. The PPIO model is suited for use with AI agents and for visual tasks or low-latency interactive scenarios.
However, distributed architectures also face challenges when it comes to regulation, standardization and service stability. Market competition is also intensifying, as major tech players step into the arena. Aside from direct rivals such as UCloud,&nbsp;Alibaba&nbsp;(BABA.US; 9988.HK),&nbsp;Baidu&nbsp;(BIDU.US; 9888.HK) &nbsp;and&nbsp;Kingsoft Cloud&nbsp;(3896.HK) are building up their own AI computing power and edge nodes. To maintain its position, PPIO would need to stay ahead of the game for platform experience, pricing and international reach.
To that end, PPIO does need external financing to keep expanding and to avoid a liquidity crunch, having around only 114 million yuan in cash on hand and a net debt of 696 million yuan.
The streaming service PPTV, which never went public, could be viewed as a missed opportunity for founder Yao. The cloud computing firm PPIO offers a second chance at stock market success, if the company can effectively plug into the surging demand for AI computing.

Asia

IPOs

Opinion

PPIO Eyes Next AI Frontier With Plans To Boost Computing Power

Deutsche Bank analyst Matt Niknam initiates coverage on A10 Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) with a Buy rating and announces Price Target of $22.

Initiation

ATEN

Deutsche Bank Initiates Coverage On A10 Networks with Buy Rating, Announces Price Target of $22

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher after President Trump said the US signed a deal with China, with China's Ministry of Commerce reportedly confirming a trade framework. Israel-Iran ceasefire efforts and stronger-than-expected consumer sentiment data may also be lifting market outlook.

The U.S. Food and Drug Administration (FDA) approved label updates for Bristol Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso-cel) for large B cell lymphoma (LBCL) and other lymphomas and Abecma (idecabtagene vicleucel; ide-cel) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">for multiple myeloma</a>.
In the first quarter of 2025, Bristol Myers Squibb reported Abecam sales of $103 million, up 26% year over year, and Breyanzi sales <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44986472/bristol-myers-delivers-upbeat-2025-forecast-after-beating-q1-wall-street-expectations-says-guidance-includes-china-tariffs-impact" rel="noreferrer noopener">jumped 146% to $204 million</a>.
The company said in a statement on Thursday that these label updates reduce certain patient monitoring requirements and remove the Risk Evaluation and Mitigation Strategy (REMS) programs that had been in place since each product <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46131412/u-s-food-and-drug-administration-approves-streamlined-patient-monitoring-requirements-and-removal-" rel="noreferrer noopener">was initially approved</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/legal/25/06/46098969/bristol-myers-faces-scrutiny-for-allegedly-rigging-market-on-2b-cancer-drug" rel="noreferrer noopener">Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2 Billion Cancer Drug</a>
The company says about 2 in 10 eligible patients receive it due to the confluence of complex logistical and geographic barriers affecting patients and providers.
The FDA has approved the reduction or removal of specific patient monitoring requirements for Breyanzi and Abecma across both labels.
These prolonged requirements burdened healthcare delivery systems and certain patients and their care partners, particularly those who live far from certified cell therapy treatment centers.
Driving restrictions post-treatment have been reduced from eight weeks to two weeks. The requirement to remain within proximity of a healthcare facility after infusion has also been shortened from four weeks to two weeks.
The FDA has also approved the removal of the REMS requirement from each product label. A REMS program is often required to help mitigate known or potential risks associated with new drugs or therapies.
The FDA has since determined that the established management guidelines and extensive experience of the medical hematology/oncology community are sufficient to diagnose and manage the risks of side effects, including cytokine release syndrome (CRS) and neurologic toxicities (NTs), without a REMS for the class of CD19- and BCMA-directed autologous CAR T cell therapies.
In April 2024, the FDA said it would now&nbsp;require boxed warnings, the highest safety-related caution for medications, for all chimeric antigen <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38334543/fda-mandates-boxed-warning-for-bristol-myers-johnson-johnson-car-t-based-blood-cancer-therapies" rel="noreferrer noopener">receptor (CAR) T-cell therapies</a>.&nbsp;
According to the agency, these blood cancer treatments may pose a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36736043/focus-on-bristol-myers-gilead-sciences-johnson-johnson-novartis-fda-to-issue-classwide-black-box-" rel="noreferrer noopener">risk of secondary cancers</a>.
Price Action: BMY stock is trading higher by 0.40% to $46.84 last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46139132/spain-accuses-novo-nordisk-of-covert-advertising-for-prescription-weight-loss-drugs" target="_blank" rel="noreferrer noopener">Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers

Citigroup analyst Ygal Arounian maintains Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) with a Neutral and raises the price target from $4.8 to $7.

BMBL

Citigroup Maintains Neutral on Bumble, Raises Price Target to $7

SEED

Origin Agritech shares are trading lower after the company reported H1 financial results.

Westinghouse Air Brake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) has outperformed the market over the past 5 years by 14.53% on an annualized basis producing an average annual return of 29.34%. Currently, Westinghouse Air Brake has a market capitalization of $35.66 billion. 
Buying $100 In WAB: If an investor had bought $100 of WAB stock 5 years ago, it would be worth $363.36 today based on a price of $208.38 for WAB at the time of writing.
<h3>Westinghouse Air Brake's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751038214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Westinghouse Air Brake 5 Years Ago Would Be Worth This Much Today

Vor Biopharma shares are trading higher after Baird raised its price target on the stock from $0.25 to $1.

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074615/Yusys-0627-900x600-1.png" alt="" class="wp-image-14976" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074615/Yusys-0627-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074615/Yusys-0627-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074615/Yusys-0627-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The Baidu-backed provider of technology services for banks reported falling revenue last year, reflecting a challenging environment for its customers
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Shenzhen-listed Yusys has filed for a Hong Kong IPO at a time when its bank customers are struggling</li>
<li>The company's revenue dropped by a quarter last year, forcing it to aggressively cut costs to maintain its profits</li>
</ul>
Getting investors excited about anything related to banking in China looks like a tough sell right now, as lenders grapple with multiple issues flowing from the nation's sluggish economy.
And yet that's what&nbsp;Yusys Technologies Co. Ltd.&nbsp;(300674.SZ) is trying to do as it files for a Hong Kong IPO to complement its existing listing in Shenzhen. The big challenge for the Baidu-backed company will be finding ways to convince investors of the big potential for its business helping China's banks upgrade their technology, even if that potential may lie several years down the road.
Banking isn't a sexy business to begin with, and it isn't growing fast in China. The country's weak economy has softened demand for borrowing by both consumers and companies, dampening business for banks. Those same banks also need to be extra cautious about the loans they make to avoid getting hit by defaults from shaky borrowers. Such constraints are pressuring bank profits, leading them to spend less on third-party services like the ones Yusys supplies.
Yusys' financial performance is "directly exposed to risks inherent in the banking industry," the company said in its recently filed&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107460/documents/sehk25061801848.pdf">IPO document</a>.
Yusys' latest annual results show how the growing chill for Chinese banks is infecting their third-party suppliers. The company's revenue dropped by a quarter to about 4 billion yuan ($557 million) last year, according to its prospectus filed last Thursday. It derives most of its revenue from services that help banks digitalize their operations, and its customers include China's "big four" national banks, as well as the country's monetary authority and policy lenders.
The big four banks' combined profit grew just 2% last year as they struggled to boost lending. Their weak loan growth was compounded by declines in interest margins as China's central bank cut interest rates to stimulate the economy. The outlook for banks continues to be bleak this year as well, as economic conditions in China remain gloomy despite various government efforts to stimulate spending.
Despite the falling revenue last year, Yusys managed to record net profit growth through a cost reduction campaign. It may resort to more cost-cutting this year to shore up its profits, even though such a strategy could undermine its longer-term prospects.
Leading last year's cost cuts were Yusys' 24% reduction in R&amp;D spending, the largest component of its operating expenses. More specifically, the company slashed expenses related to benefits for R&amp;D personnel, which account for more than 90% of spending for the category. Yusys attributed the steep cuts to its shifting resource allocation based on future plans and business requirements.
That hardly looks promising since Yusys is a technology company and thus needs to continuously enhance its offerings to retain existing customers and find new ones. Innovation is crucial for the company, particularly because it operates in a highly competitive sector. In its prospectus, the company says it is the largest listed provider of banking fintech services in China. But it also points out its market share is just 2%, showing there are lot of competitors looking to take away its business.
<h4 class="wp-block-heading">Firmly profitable</h4>
That said, Yusys may still appeal to investors looking for a company that has well-established operations and is firmly profitable. It has been around for quite some time, founded in 1999 and going public in New York eight years later, before privatizing in 2013. Five years later, it became a publicly traded company again by listing on Shenzhen's Nasdaq-style ChiNext board for growth companies. Its current investors include Baidu, which hold a 3.6% stake.
Yusys has served more than 1,000 customers in the last three years and has been profitable throughout that time. The company's business should indeed have strong demand, especially in the current market where China is encouraging companies to make technology upgrades as one of its many economic stimulus measures. Banks in China, and globally as well, are using technology like big data and AI to cut costs and improve the quality of their services and decision-making.
Technology spending by financial institutions across the world will increase about 11% annually over the next five years to reach $990 billion in 2029, according to a third-party projection included in Yusys' prospectus. That should bode well for Yusys and its peers, since a significant amount of that spending is expected to go to the purchase of technology services provided by outside companies.
Yusys has won some significant projects this year, including the development of a platform for data management, regulatory compliance and analytics for the London branch of a major bank.
Its services can be even more attractive for smaller financial institutions that lack internal resources to develop their own digital capabilities. In the first quarter of this year, a number of regional banks in China adopted the company's upgraded chatbot software.
Yet its customers are likely to rein in their own spending on third-party services as their business suffers in China's slowing economy. Yusys says it is looking to win more business from foreign banks to offset that risk, but its revenue from overseas customers is negligible for now.
Yusys' Shenzhen-listed shares have risen substantially since its Shenzhen IPO to trade at a healthy price-to-earnings (P/E) ratio of 47 and a decent price-to-sales (P/S) ratio of 5. By comparison, Tencent-backed&nbsp;Linklogis&nbsp;(9959.HK), which provides cloud-based software-as-a-service (SaaS) platforms for supply-chain financing, is losing money and trades at a lower P/S ratio is 3.3. The China-listed shares of the big four state-run banks also trade at P/S ratios in the 3 to 4 range.
Whether Yusys can fetch a higher valuation than its peers with the Hong Kong listing could be challenging, since Hong Kong investors often value companies lower than their Mainland Chinese counterparts. The company's revenue is expected to return to growth this year, with seven analysts polled by Yahoo Finance forecasting an 11% rise to 4.4 billion yuan. But even with that growth, the figure would still be well below its 2023 revenue,
Such lackluster prospects may not win over investors to Yusys' IPO, especially as it makes its listing into one of the hottest – but also most crowded – IPO markets that Hong Kong has seen for several years.

Equities

Yusys Seeks A Second Listing In Hong Kong

<a href="https://www.nytimes.com/2025/06/27/business/g7-tax-plan-trump.html?searchResultPosition=1">https://www.nytimes.com/2025/06/27/business/g7-tax-plan-trump.html?searchResultPosition=1</a>

'G7 Backs Plan for 'Side-by-Side' Tax System to Avoid U.S. Fight'- New York Times

Attention is shifting from cryptocurrencies to equities and publicly traded companies like Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), and Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>), which have surged ahead in <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46131195/cathie-woods-thursday-crypto-moves-ark-unloads-nearly-25-million-in-coinbase-block-stocks">performance over the past month</a>.
What Happened: In an X <a href="https://x.com/MilkRoadDaily/status/1938318830981570978">post</a> on June 27, Milk Road Daily pointed out this outperformance.
Circle has led the pack with a 162% return in the last 30 days, while Coinbase and Robinhood gained between 30% and 35% during the same period. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) logged negative returns ranging from -2% to -18% over the same timeframe.
Scarcity Meets Demand
There are relatively few crypto-linked public equities available, yet institutional and retail investors are hungry for exposure to crypto-adjacent plays, especially ones that have real revenue, growth potential and U.S. government support.
Token vs. Equity Market Dynamics
While equities benefit from limited supply and strong fundamentals, the token market is suffering the opposite fate as capital flows into tokens are muted compared to past cycles. 
At the same time, the number of tokens continues to explode, creating over-saturation and weakening price performance.
This mismatch of low demand and excessive supply is weighing heavily on altcoins, many of which are bleeding value despite brief speculative rallies.
Also Read: <a href="https://fr.benzinga.com/quote/cryptocurrency/25/06/46112072/coinbase-is-the-amazon-of-crypto-services-price-target-boosted-to-510-bernstein">Coinbase Is The &#8216;Amazon Of Crypto Services&#8217;, Price Target Boosted To $510: Bernstein</a>
Why It Matters: Crypto trader ResDegen <a href="https://x.com/resdegen/status/1937588394114142462">noted</a> that Robinhood, Circle, and Coinbase have clear business models, real revenue streams, and growing legitimacy with regulators. 
They offer a tangible value proposition that's drawing capital away from more speculative crypto assets.
As Kaizen <a href="https://x.com/KAIZ3NS/status/1936096315391312221">noted</a> on X, one of the defining features of this cycle is that only a handful of stocks and coins have shown real outperformance, namely crypto equities and a few large caps. 
TradFi currently has a stronger appetite for crypto-linked equities than for alt tokens.
Even Web3-native investors are beginning to shift their view. 
Trader David Arnal <a href="https://x.com/davidarngar/status/1936117933907787929">said</a> he considers Coinbase a safer long-term bet than even Bitcoin, citing teal revenue, government support and a market capitalization comparable to Solana. 
"COIN is the best stock to own for the next few months," he added.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46097909/robinhood-ceo-highlights-retail-investor-interest-in-nvidia-tesla-despite-middle-east-tensions-barely-a-blip">Robinhood CEO Highlights Retail Investor Interest In Nvidia, Tesla Despite Middle East Tensions: &#8216;Barely A Blip&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Fintech news covering the emerging Financial Technology services sector

Fintech

$BTC

$ETH

$SOL

CRCL

HOOD

Bitcoin, Ethereum, Solana Lag Behind Robinhood, Circle, Coinbase: Why Do Crypto Stocks Outperform Coins?

Press Releases

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

Earnings

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

Comments

IDEAYA Biosciences

ニュース

最新ニュース IDEAYA Biosciences (NASDAQ:IDYA) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル